Temporal and spatial transcriptional fingerprints by antipsychotic or propsychotic drugs in mouse brain

PLoS ONE

Volumn 10, Issue 2, 2015, Pages

  Sakuma, Kensuke ^a   Komatsu, Hidetoshi ^a   Maruyama, Minoru ^a   Imaichi, Sachiko ^a   Habata, Yugo ^a   Mori, Masaaki ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; DIZOCILPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; METHAMPHETAMINE; NEUROLEPTIC AGENT; OLANZAPINE; PHENCYCLIDINE; QUINPIROLE; SULPIRIDE; TRANSCRIPTOME; BENZODIAZEPINE DERIVATIVE; DIZOCILPINE MALEATE; PSYCHEDELIC AGENT;

ANIMAL EXPERIMENT; ARC GENE; ARTICLE; BRAIN REGION; CCN1 GENE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG PROTEIN BINDING; DRUG SCREENING; EGR1 GENE; EGR2 GENE; EGR3 GENE; FINGER DERMATOGLYPHICS; GENE EXPRESSION; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; HIPPOCAMPUS; IMMEDIATE EARLY GENE; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; ONCOGENE C FOS; POSITIVE SYNDROME; PREFRONTAL CORTEX; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SGK1 GENE; AGONISTS; ANIMAL; BRAIN; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; PROCEDURES;

MURINAE;

ANIMALS; ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; BENZODIAZEPINES; BRAIN; DIZOCILPINE MALEATE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HALLUCINOGENS; HALOPERIDOL; METHAMPHETAMINE; MICE; PHENCYCLIDINE; RECEPTORS, DOPAMINE D2;

EID: 84923286812     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0118510     Document Type: Article

References (55)

1. Insel TR. Rethinking schizophrenia. Nature. 2010;468(7321):187-93. doi: 10.1038/nature09552 PMID: 21068826
2. Arguello PA, Gogos JA. Modeling madness in mice: one piece at a time. Neuron. 2006;52(1):179-96. PMID: 17015235
3. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther. 1989;251(1):238-46. PMID: 2571717
4. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996;124(1-2):57-73.
5. Hirose T, Kikuchi T. Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist. J Med Invest. 2005;52 Suppl: 284-90. PMID: 16366516
6. Kantrowitz J, Javitt DC. Glutamatergic transmission in schizophrenia: from basic research to clinical practice. Curr Opin Psychiatry. 2012;25(2):96-102. doi: 10.1097/YCO.0b013e32835035b2 PMID: 22297716
7. Coyle JT, Balu D, Benneyworth M, Basu A, Roseman A. Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia. Dialogues Clin Neurosci. 2010;12(3):359-82. PMID: 20954431
8. Leslie JH, Nedivi E. Activity-regulated genes as mediators of neural circuit plasticity. Prog Neurobiol. 2011;94(3):223-37. doi: 10.1016/j.pneurobio.2011.05.002 PMID: 21601615
9. Gonzalez-Maeso J, Yuen T, Ebersole BJ, Wurmbach E, Lira A, Zhou M, et al. Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2003;23(26):8836-43. PMID: 14523084
10. Pratt J, Winchester C, Dawson N, Morris B. Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap. Nat Rev Drug Discov. 2012;11(7):560-79. doi: 10.1038/nrd3649 PMID: 22722532
11. Gonzalez-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, et al. Hallucinogens recruit specific cortical 5-HT (2A) receptor-mediated signaling pathways to affect behavior. Neuron. 2007;53(3):439-52. PMID: 17270739
12. Clayton DF. The genomic action potential. Neurobiol Learn Mem. 2000;74(3):185-216. PMID: 11031127
13. Okuno H. Regulation and function of immediate-early genes in the brain: beyond neuronal activity markers. Neurosci Res. 2011;69(3):175-86. doi: 10.1016/j.neures.2010.12.007 PMID: 21163309
14. Yamada K, Gerber DJ, Iwayama Y, Ohnishi T, Ohba H, Toyota T, et al. Genetic analysis of the calcineurin pathway identifies members of the EGR gene family, specifically EGR3, as potential susceptibility candidates in schizophrenia. Proc Natl Acad Sci U S A. 2007;104(8):2815-20. PMID: 17360599
15. Wirtshafter D, Sheppard AC. Role of dopamine D2 receptors in the striatal immediate early gene response to amphetamine in reserpinized rats. Brain research bulletin. 2003;62(1):77-83. PMID: 14596895
16. Robbins MJ, Critchlow HM, Lloyd A, Cilia J, Clarke JD, Bond B, et al. Differential expression of IEG mRNA in rat brain following acute treatment with clozapine or haloperidol: a semi-quantitative RT-PCR study. J Psychopharmacol. 2008;22(5):536-42. doi: 10.1177/0269881107081521 PMID: 18208916
17. Ito T, Hiraoka S, Kuroda Y, Ishii S, Umino A, Kashiwa A, et al. Effects of schizophrenomimetics on the expression of the CCN1 (CYR 61) gene encoding a matricellular protein in the infant and adult neocortex of the mouse and rat. Int J Neuropsychopharmacol. 2007;10(6):717-25. PMID: 17608974
18. Greenberg ME, Ziff EB. Stimulation of 3T3 cells induces transcription of the c-fos proto-oncogene. Nature. 1984;311(5985):433-8. PMID: 6090941
19. Morgan JI, Cohen DR, Hempstead JL, Curran T. Mapping patterns of c-fos expression in the central nervous system after seizure. Science. 1987;237(4811):192-7. PMID: 3037702
20. Lyford GL, Yamagata K, Kaufmann WE, Barnes CA, Sanders LK, Copeland NG, et al. Arc, a growth factor and activity-regulated gene, encodes a novel cytoskeleton-associated protein that is enriched in neuronal dendrites. Neuron. 1995;14(2):433-45. PMID: 7857651
21. Okuno H, Akashi K, Ishii Y, Yagishita-Kyo N, Suzuki K, Nonaka M, et al. Inverse synaptic tagging of inactive synapses via dynamic interaction of Arc/Arg3.1 with CaMKIIbeta. Cell. 2012;149(4):886-98. doi: 10.1016/j.cell.2012.02.062 PMID: 22579289
22. Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006;20(5):389-409. PMID: 16696579
23. Ruxton GD. The unequal variance t-test is an underused alternative to Student's t-test and the Mann-Whitney U test. Behavioral Ecology. 2006;17(4):688-90.
24. Boulay D, Bergis O, Avenet P, Griebel G. The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology. 2010;35(2):416-27. doi: 10.1038/npp. 2009.144 PMID: 19759529
25. Ma M, Ren Q, Fujita Y, Ishima T, Zhang JC, Hashimoto K. Effects of AS2586114, a soluble epoxide hydrolase inhibitor, on hyperlocomotion and prepulse inhibition deficits in mice after administration of phencyclidine. Pharmacology, biochemistry, and behavior. 2013;110:98-103. doi: 10.1016/j.pbb. 2013.06.005 PMID: 23792539
26. Yui K, Ikemoto S, Ishiguro T, Goto K. Studies of amphetamine or methamphetamine psychosis in Japan: relation of methamphetamine psychosis to schizophrenia. Annals of the New York Academy of Sciences. 2000;914:1-12. PMID: 11085303
27. Sharp FR, Tomitaka M, Bernaudin M, Tomitaka S. Psychosis: pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia? Trends Neurosci. 2001;24(6):330-4. PMID: 11356504
28. Link W, Konietzko U, Kauselmann G, Krug M, Schwanke B, Frey U, et al. Somatodendritic expression of an immediate early gene is regulated by synaptic activity. Proc Natl Acad Sci U S A. 1995;92(12):5734-8. PMID: 7777577
29. Steward O, Wallace CS, Lyford GL, Worley PF. Synaptic activation causes the mRNA for the IEG Arc to localize selectively near activated postsynaptic sites on dendrites. Neuron. 1998;21(4):741-51. PMID: 9808461
30. Coba MP, Valor LM, Kopanitsa MV, Afinowi NO, Grant SG. Kinase networks integrate profiles of Nmethyl-D-aspartate receptor-mediated gene expression in hippocampus. J Biol Chem. 2008;283(49):34101-7. doi: 10.1074/jbc. M804951200 PMID: 18815127
31. Konradi C, Leveque JC, Hyman SE. Amphetamine and dopamine-induced immediate early gene expression in striatal neurons depends on postsynaptic NMDA receptors and calcium. The Journal of neuroscience: the official journal of the Society for Neuroscience. 1996;16(13):4231-9. PMID: 8753884
32. Manji HK, Gottesman II, Gould TD. Signal transduction and genes-to-behaviors pathways in psychiatric diseases. Sci STKE. 2003;2003(207): pe49. PMID: 14600293
33. Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S, et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet. 2002;71(4):877-92. PMID: 12145742
34. Jacobson C, Duggan D, Fischbach G. Neuregulin induces the expression of transcription factors and myosin heavy chains typical of muscle spindles in cultured human muscle. Proc Natl Acad Sci U S A. 2004;101(33):12218-23. PMID: 15302938
35. Tsai KJ, Chen SK, Ma YL, Hsu WL, Lee EH. sgk, a primary glucocorticoid-induced gene, facilitates memory consolidation of spatial learning in rats. Proc Natl Acad Sci U S A. 2002;99(6):3990-5. PMID: 11891330
36. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31-41. doi: 10.1016/S0140-6736 (08) 61764-X PMID: 19058842
37. Surmeier DJ, Ding J, Day M, Wang Z, Shen W. D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci. 2007;30(5):228-35. PMID: 17408758
38. Ikemoto S. Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex. Brain Res Rev. 2007;56(1):27-78. PMID: 17574681
39. Deutch AY, Lee MC, Iadarola MJ. Regionally specific effects of atypical antipsychotic drugs on striatal Fos expression: The nucleus accumbens shell as a locus of antipsychotic action. Mol Cell Neurosci. 1992;3(4):332-41. PMID: 19912876
40. Haleem DJ, Batool F, Khan NH, Kamil N, Ali O, Saify ZS, et al. Differences in the effects of haloperidol and clozapine on brain serotonin and dopamine metabolism and on tests related to extrapyramidal functions in rats. Med Sci Monit. 2002;8(9): BR354-61. PMID: 12218936
41. Flores-Hernandez J, Cepeda C, Hernandez-Echeagaray E, Calvert CR, Jokel ES, Fienberg AA, et al. Dopamine enhancement of NMDA currents in dissociated medium-sized striatal neurons: role of D1 receptors and DARPP-32. Journal of neurophysiology. 2002;88(6):3010-20. PMID: 12466426
42. Beazely MA, Tong A, Wei WL, Van Tol H, Sidhu B, MacDonald JF. D2-class dopamine receptor inhibition of NMDA currents in prefrontal cortical neurons is platelet-derived growth factor receptordependent. Journal of neurochemistry. 2006;98(5):1657-63. PMID: 16879713
43. Stahl SM. Stahl's Essential Psychopharmacology 4th edition: Neuroscientific Basis and Practical Applications. Cambridge University Press. 2013.
44. Masri B, Salahpour A, Didriksen M, Ghisi V, Beaulieu JM, Gainetdinov RR, et al. Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proc Natl Acad Sci U S A. 2008;105(36):13656-61. doi: 10.1073/pnas.0803522105 PMID: 18768802
45. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51(3):199-214. PMID: 8122957
46. Gunduz-Bruce H. The acute effects of NMDA antagonism: from the rodent to the human brain. Brain Res Rev. 2009;60(2):279-86. doi: 10.1016/j.brainresrev. 2008.07.006 PMID: 18703087
47. Laruelle M, Frankle WG, Narendran R, Kegeles LS, Abi-Dargham A. Mechanism of action of antipsychotic drugs: from dopamine D (2) receptor antagonism to glutamate NMDA facilitation. Clin Ther. 2005;27 Suppl A: S16-24. PMID: 16198197
48. Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov. 2004;3(4):353-9. PMID: 15060530
49. Benturquia N, Courtin C, Noble F, Marie-Claire C. Involvement of D1 dopamine receptor in MDMAinduced locomotor activity and striatal gene expression in mice. Brain research. 2008;1211:1-5. doi: 10.1016/j.brainres.2008.03.016 PMID: 18433738
50. Yamagata K, Suzuki K, Sugiura H, Kawashima N, Okuyama S. Activation of an effector immediateearly gene arc by methamphetamine. Annals of the New York Academy of Sciences. 2000;914:22-32. PMID: 11085305
51. Ferguson SM, Norton CS, Watson SJ, Akil H, Robinson TE. Amphetamine-evoked c-fos mRNA expression in the caudate-putamen: the effects of DA and NMDA receptor antagonists vary as a function of neuronal phenotype and environmental context. Journal of neurochemistry. 2003;86(1):33-44. PMID: 12807422
52. Bertran-Gonzalez J, Bosch C, Maroteaux M, Matamales M, Herve D, Valjent E, et al. Opposing patterns of signaling activation in dopamine D1 and D2 receptor-expressing striatal neurons in response to cocaine and haloperidol. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2008;28(22):5671-85. doi: 10.1523/JNEUROSCI.1039-08.2008 PMID: 18509028
53. Wood S, Sage JR, Shuman T, Anagnostaras SG. Psychostimulants and cognition: a continuum of behavioral and cognitive activation. Pharmacological reviews. 2014;66(1):193-221. doi: 10.1124/pr.112. 007054 PMID: 24344115
54. Panenka WJ, Procyshyn RM, Lecomte T, MacEwan GW, Flynn SW, Honer WG, et al. Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings. Drug and alcohol dependence. 2013;129(3):167-79. doi: 10.1016/j.drugalcdep. 2012.11.016 PMID: 23273775
55. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. (4th edition): San Diego: Academic Press. 1998.